Extending Human Healthspan: Beyond Weight Loss to Metabolic Resilience (JPM2026 • San Francisco)

​✦ Panel discussion & networking event • JPM 2026 ✦

​The next frontier in metabolic medicine won't be measured on a scale.

​Blockbuster GLP-1 receptor agonists have transformed the treatment of obesity—and revealed a crucial insight: The most impactful metabolic interventions deliver benefits far beyond weight reduction, including improvements in cardiovascular risk, inflammation, and systemic metabolic function. 

​Join BioAge and our panelists from biopharma and academia for a discussion of the challenges and opportunities at this exciting frontier, with topics including

• ​Next-generation targets and complementary mechanisms

• ​Designing drugs for the interconnected biology of metabolic health

• ​Leveraging the biology of aging to treat the root of metabolic diseases

​——— ✦ ———

​Moderator:

• ​Kristen Fortney, PhD - CEO & co-founder, BioAge

​Panelists:

• ​Christopher O'Donnell, MD - Global Head, Cardiovascular and Metabolism Translational Medicine, Novartis BioMedical Research

• ​Mark Pruzanski, MD - CEO, Alentis Therapeutics; formerly CEO, Versanis

• ​Mike Snyder, PhD - Professor of Genetics, Stanford University School of Medicine

• ​Hanadie Yousef, PhD - Co-Founder, Director, & Executive Advisor, Juvena Therapeutics

​——— ✦ ———

​Doors open at 4 PM (PT). A lively discussion (5–6 PM) will be followed by Q&A from the audience, with networking over cocktails and appetizers before and afterward.